Yeztugo access in Bangladesh: the DGDA named-patient pathway

How patients in the People's Republic of Bangladesh legally obtain Yeztugo (lenacapavir) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Yeztugo (lenacapavir) for twice-yearly subcutaneous pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Bangladeshi patients need Yeztugo through the named-patient pathway

The People's Republic of Bangladesh operates a structured pharmaceutical regulatory environment. Yeztugo (lenacapavir) is regulated through DGDA (Directorate General of Drug Administration) channels, and a Bangladeshi family asking for Yeztugo is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Yeztugo's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bangladesh or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the DGDA named-patient pathway is the mechanism that connects a Bangladeshi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Yeztugo is a first-in-class long-acting HIV-1 capsid inhibitor that binds the conserved hexamer interface of the viral capsid, disrupting multiple stages of the viral lifecycle, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

Current regulatory status of Yeztugo in Bangladesh

Yeztugo (lenacapavir; Gilead Sciences) is a first-in-class HIV-1 capsid inhibitor, FDA-approved for twice-yearly subcutaneous pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing at least 35 kg. As of 2026-05-31, no DGDA marketing authorisation for lenacapavir is publicly indexed on the DGDA Registered Imported Drugs list. The drug is also relatively recent in the FDA register (2025 PrEP approval; earlier 2022 approval for heavily treatment-experienced HIV) and the local registration timeline is not publicly documented.

The Bangladeshi public-health framework for HIV care runs primarily through the National AIDS / STD Programme (NASP) of the Directorate General of Health Services (DGHS), with antiretroviral therapy procurement coordinated centrally and donor-supported. Pre-exposure prophylaxis programmes in Bangladesh use oral TDF/FTC or TDF/3TC as the dominant regimen; long-acting injectable PrEP is not a routine NASP-supplied offering as of 2026-05-31. Source: National AIDS / STD Programme, DGHS.

Cross-border access to Yeztugo therefore proceeds under Section 13 of the Drugs (Control) Ordinance 1982 as a case-by-case import permission through a BMDC-registered infectious-disease physician at a tertiary hospital or HIV clinic. Bangladesh maintains a low (concentrated) HIV epidemic and population-level PrEP demand is limited; named-patient files for lenacapavir are most often initiated by patients with documented elevated risk, by sero-discordant couples, or by patients who have failed adherence on oral PrEP.

Last DGDA bulletin observed touching imported HIV-product regulation: 2025-01-14 Guideline for Quality Assurance of Locally Sourced Medical Products. Last verified by ARCH-74: 2026-05-31.

Named tertiary centres in Bangladesh where Yeztugo is dispensed

Lenacapavir is administered as two 463.5 mg subcutaneous injections at baseline (alongside an oral loading regimen) and one 927 mg subcutaneous injection every 26 weeks thereafter. The drug is dispensed where infectious-disease specialty, HIV-care experience, and subcutaneous-injection administration converge:

ICDDR,B (International Centre for Diarrhoeal Disease Research, Bangladesh), Mohakhali, Dhaka - HIV / AIDS clinical research and care service; one of the country's principal HIV-care centres for complex cases. Source: ICDDR,B.
National Institute of Diseases of the Chest and Hospital (NIDCH), Mohakhali, Dhaka - HIV co-infection and TB-HIV service.
National AIDS / STD Programme (NASP) sentinel HIV-care sites in Dhaka, Chattogram, and Sylhet - public-sector HIV clinics; NASP referral required for case routing.
Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka - Department of Internal Medicine / Infectious Diseases sub-clinic.
Square Hospitals Limited, Dhaka - private multi-specialty tertiary; infectious-disease consultant roster handles a small volume of private HIV-PrEP cases.

HIV-PrEP cases in Bangladesh route through specialist channels rather than general practice; the prescribing physician's experience with PrEP-eligibility documentation (recent HIV-negative test, hepatitis B status, renal function, behavioural-risk assessment) is the main differentiator across centres.

Local pricing reference for Yeztugo in Bangladesh

US WAC reference for Yeztugo (lenacapavir, the PrEP twice-yearly subcutaneous regimen) is in the order of USD 14,000 to USD 15,000 per six-month dose at US list price; for two doses across one year the reference annual band is roughly USD 28,000 to USD 30,000. Gilead has signalled tiered pricing for low- and middle-income access and a generic-licensing agreement with multiple manufacturers; as of 2026-05-31, no published Bangladesh-specific tiered price has been observed. Source: Yeztugo FDA Prescribing Information; Gilead public statements on access.

No public BDT reference price for lenacapavir has been observed on DGDA, NASP, ICDDR,B, or major-importer published lists as of 2026-05-31. Where Gilead or a sublicensed generic manufacturer publishes a Bangladesh-tier list price in future, the named-patient quotation we issue will move to that reference rather than US WAC.

Price snapshot date: 2026-05-31. Oral loading dose component (lenacapavir 600 mg orally on Day 1 and Day 2 of the initial regimen) is dispensed alongside the subcutaneous injection and is billed by the dispensing centre.

Country-specific access barriers for Yeztugo in Bangladesh

HIV is a stigmatised condition in Bangladesh; the principal non-procedural barrier to PrEP access is patient willingness to be entered in a hospital pharmacy file by name. Confidentiality safeguards at ICDDR,B and NASP sentinel sites are documented in their service charters; the BMDC-registered prescribing physician retains the duty of confidentiality. The hospital file does not require disclosure to family or employer.

Public-sector funding for long-acting injectable PrEP in Bangladesh is not established as of 2026-05-31. NASP-supplied oral PrEP (tenofovir-emtricitabine) is the routine offering. Donor-funded HIV-care programmes (Global Fund, UNAIDS-affiliated) do not currently distribute lenacapavir for PrEP in Bangladesh as a routine offering, although programme parameters change and the prescribing centre should verify current eligibility at the time of file submission.

Private-insurance coverage of PrEP is variable. Group-corporate plans (Pragati Life, Delta Life, MetLife Bangladesh, Green Delta, Pioneer) cover formal-sector employees; HIV-PrEP coverage is policy-specific and is sometimes excluded under preventive-care exclusions. Self-pay is the dominant funding pattern for a Bangladeshi patient seeking lenacapavir PrEP outside a research or programmatic channel.

The twice-yearly dosing cadence is materially favourable from a continuity standpoint - permits and shipments are infrequent compared with chronic monthly biologic therapies. Cold-chain logistics for the 2 to 8 degree Celsius prefilled vials are established at Dhaka airport. The binding clinical-readiness criterion is the recent (within 7 days) documented HIV-negative test, hepatitis-B serology, and renal-function assessment that the file must reference.

Recent local regulatory news touching Yeztugo or its drug class in Bangladesh

No DGDA bulletin specifically naming lenacapavir, the HIV-1-capsid-inhibitor class, or the long-acting-injectable PrEP category has been observed in the last twelve months on the DGDA all-categories notices page as of 2026-05-31. Adjacent context:

2025-01-14 - DGDA Guideline for Quality Assurance of Locally Sourced Medical Products tightens lot-by-lot QA expectations for imported biologic and injectable finished products. Source: DGDA Guideline PDF.
The National AIDS / STD Programme continues to update HIV-PrEP guidance; programme parameters and PrEP-eligible-patient definitions should be reverified at the time of file submission. Source: NASP, DGHS.
The Bangladesh medicine-regulation reform Bill (planned 1982 Ordinance replacement) is in active consultation and may restructure the case-by-case import-permission mechanism that currently underpins long-acting-injectable PrEP access. Source: Dhaka Tribune coverage.

What your physician needs to provide

For a Bangladeshi-licensed specialist prescribing Yeztugo through the DGDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for twice-yearly subcutaneous pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Yeztugo is the appropriate next step given a first-in-class long-acting HIV-1 capsid inhibitor that binds the conserved hexamer interface of the viral capsid, disrupting multiple stages of the viral lifecycle.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Yeztugo (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Bangladeshi license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

Common questions about Yeztugo in Bangladesh

Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Yeztugo is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA? The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Yeztugo at home? The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Yeztugo cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Yeztugo specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Yeztugo case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Yeztugo and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Yeztugo case Or message us on WhatsApp